Aldeyra Therapeutics, Inc. (ALDX) Financial Statements (2026 and earlier)

Company Profile

Business Address 131 HARTWELL AVENUE
LEXINGTON, MA 02421
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)
Annual | Quarterly

3/31/2026
MRQ
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 70,041,25446,624,180 29,881,520229,790,98977,858,311
Cash and cash equivalent 70,041,254   229,790,98977,858,311
Short-term investments  46,624,180 29,881,520  
Prepaid expense407,194408,091340,388   
Other undisclosed current assets1,335,00857,040,207147,469,945151,141,5932,961,7815,200,957
Total current assets:71,783,456104,072,478147,810,333181,023,113232,752,77083,059,268
Noncurrent Assets
Operating lease, right-of-use asset275,861266,955510,814249,265351,863233,310
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization   5,76419,27932,48759,925
Deferred costs  267,261    
Total noncurrent assets:275,861534,216516,578268,544384,350293,235
TOTAL ASSETS:72,059,317104,606,694148,326,911181,291,657233,137,12083,352,503
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,278,75812,298,8206,874,52114,199,51011,543,0558,516,403
Accounts payable158,461180,4531,338,057133,6251,019,702381,638
Accrued liabilities6,120,29712,118,3675,536,46414,065,88510,523,3538,134,765
Deferred revenue 6,000,0006,000,000    
Debt15,249,63231,37215,146,546911,763 3,659,776
Other undisclosed current liabilities280,537271,631239,183249,265229,607233,310
Total current liabilities:27,808,92718,601,82322,260,25015,360,53811,772,66212,409,489
Noncurrent Liabilities
Long-term debt and lease obligation15,000,00015,000,00015,000,00014,923,09015,628,93511,434,456
Long-term debt, excluding current maturities15,000,00015,000,00015,000,00014,923,09015,503,70311,434,456
Liabilities, other than long-term debt   271,631   
Operating lease, liability   271,631 125,232 
Other undisclosed noncurrent liabilities(15,000,000) (9,000,000) (125,232) 
Total noncurrent liabilities:  15,000,0006,271,63114,923,09015,628,93511,434,456
Total liabilities:27,808,92733,601,82328,531,88130,283,62827,401,59723,843,945
Equity
Equity, attributable to parent44,250,39071,004,871119,795,030151,008,029205,735,52359,508,558
Common stock60,16359,64859,19658,56058,08138,667
Additional paid in capital528,147,480521,018,373513,994,982507,770,045500,369,444296,385,619
Accumulated other comprehensive income (loss)  37,442 (103,938)  
Accumulated deficit(483,957,253)(450,110,592)(394,259,148)(356,716,638)(294,692,002)(236,915,728)
Total equity:44,250,39071,004,871119,795,030151,008,029205,735,52359,508,558
TOTAL LIABILITIES AND EQUITY:72,059,317104,606,694148,326,911181,291,657233,137,12083,352,503

Income Statement (P&L) (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(35,265,206)(60,117,032)(42,794,083)(62,679,987)(56,219,536)(34,666,755)
Other undisclosed operating loss      (1,754,265)
Operating loss:(35,265,206)(60,117,032)(42,794,083)(62,679,987)(56,219,536)(36,421,020)
Nonoperating income (expense)1,418,5454,265,5885,251,573655,351(1,556,738)(1,611,974)
Investment income, nonoperating3,323,8556,191,8297,323,0082,349,449185,363292,224
Interest and debt expense(267,261)(1,926,241)(2,071,435)(1,694,098)(1,742,101)(1,904,198)
Loss from continuing operations before equity method investments, income taxes:(34,113,922)(57,777,685)(39,613,945)(63,718,734)(59,518,375)(39,937,192)
Other undisclosed income from continuing operations before income taxes     1,742,1011,904,198
Loss from continuing operations before income taxes:(34,113,922)(57,777,685)(39,613,945)(63,718,734)(57,776,274)(38,032,994)
Income tax expense (benefit)  (1,000)   479,265
Loss from continuing operations:(34,113,922)(57,778,685)(39,613,945)(63,718,734)(57,776,274)(37,553,729)
Loss before gain (loss) on sale of properties:✕✕✕✕✕(57,776,274)(37,553,729)
Other undisclosed net income267,2611,927,2412,071,4351,694,098  
Net loss:(33,846,661)(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)
Other undisclosed net income attributable to parent      
Net loss available to common stockholders, diluted:(33,846,661)(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)

Comprehensive Income (USD)
Annual | Quarterly

3/31/2026
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(33,846,661)(55,851,444)(37,542,510)(62,024,636)(57,776,274)(37,553,729)
Other comprehensive income (loss) (37,442) 103,938(103,938) (5,866)
Other undisclosed comprehensive loss      
Comprehensive loss:(33,884,103)(55,851,444)(37,438,572)(62,128,574)(57,776,274)(37,559,595)
Other undisclosed comprehensive income, net of tax, attributable to parent 37,442    
Comprehensive loss, net of tax, attributable to parent:(33,884,103)(55,814,002)(37,438,572)(62,128,574)(57,776,274)(37,559,595)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: